杂志简称：haematologica
中文译名：《血液学》
收录属性：scie（2024版）, 目次收录（维普）,英文期刊,
自引率：3.90%
投稿方向：医学、hematology 血液学
SCI/E期刊基本信息
出版周期：月刊 地区：意大利
中科院分区：2区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：OA期刊
国际标准刊号：ISSN0390-6078；EISSN1592-8721
杂志语言：英语
出版国家：意大利
杂志官网 联系方式
出版地址：FERRATA STORTI FOUNDATION,VIA GIUSEPPE BELLI 4,PAVIA,ITALY,27100
杂志邮箱：
投稿网址：http://submit-haematol.highwire.org/
杂志官方网址：http://haematologica.org/
出版商网址：http://www.ferrata-storti.org
杂志投稿要求
投稿须知【杂志社官方网站信息】
Author Guidelines
For 'Defining the role of authors and contributors', 'Disclosure of financial and non-financial relationship and activities, and conflict of interest', and 'Responsibility in the submission and peer-review process' see Our Policies
General information
Haematologica is the main tool through which the Ferrata-Storti Foundation, a non-profit organization, promotes the dissemination of new knowledge in the field of hematology. A high quality of articles, immediate free access to everything published and the lowest possible cost for authors are the principles that inspire Haematologica management.
Haematologica considers for publication manuscripts on physiology and pathophysiology of hematopoiesis and blood cells as well as clinical studies on disorders that hematology departments take care of. Papers that focus primarily on disorders of vessels, atherosclerosis included, are outside the scope of Haematologica and will not be considered for publication.
Haematologica does not publish the results of studies that have already been published, even partially, or are going to be published in any form. Meeting abstracts are the only exception. Haematologica reserves the right to seek evidence of plagiarism.
Haematologica does not even consider for publication papers not reporting primary data whose preparation has been promoted, sponsored or supported in any way by a company whose product is discussed in the paper. Potential conflicts of interest of single authors are not considered an obstacle for publication (all authors are required to disclose competing interests during the online submission process).
Original articles. There is no limit to the number of authors, but this must be commensurate with the complexity of the study. The manuscript are to be divided into sections under the following subheadings: Abstract, Introduction, Methods, Results, Discussion, and References.
Abstract (unstructured), maximum 250 words. Articles reporting clinical trials should provide the trial registration number at the end of the abstract. Use abbreviations only for terms that occur at least twice. In this case, explain their meaning when they are first used.
Main text (Introduction, Methods, Results, Discussion) maximum 4,000 words. The Methods and Results sections can be divided with specific subtitles. The methods section (maximum 500 words) should include the most important methods that allow readers to understand the article content. When required, further information on methodology can be provided in the Supplementary data.
References, maximum 50.
Figure and Tables, maximum 8 items in total. Additional figures and tables can be published as Supplementary data.
Original articles reporting randomized trials must follow CONSORT recommendations, meta-analyses and guidelines PRISMA recommendations, observational studies STROBE recommendations, and studies of diagnostic accuracy STARD guidelines.
Review articles. As a rule, Reviews are by invitation. However, authoritative researchers can submit reviews on topics for which they have demonstrated competence. The maximum number of authors is usually limited to three. Review articles are maximum 5,000 words long (excluding abstract, tables, figure legends and references) and do not have a specific structure. The reviews should contain an unstructured abstract of maximum 250 words (abbreviations only for terms that occur at least twice), and have a maximum 100 references. Authors are encouraged to describe the methods used for locating, selecting, extracting, and synthesizing data; this is mandatory for systematic reviews (see PRISMA guidelines). The use of tables and figures is strongly encouraged (no limit to their number).
Perspective articles. The format and editorial guidelines for this type of article are the same as for the reviews. The perspective articles differ from the reviews because they do not require a systematic and exhaustive analysis of the literature, but allow authors to use literature data to freely express their personal opinion on topics and controversies relevant to hematology.
Editorials. Editorials that comment on Haematologica articles are by invitation and are published in the same issue as the commented paper. However, submission of Editorials by authoritative researchers on debated topics or important news is welcome.
Editorials have a free structure (no abstract), contain about 1,500 words (excluding tables and references), up to 20 references and may contain two display items (figures and/or tables). No more than two authors are permitted.
Guideline articles. They should produced by an international group of experts. These articles are up to 5,000 words long (excluding tables, figure legends and references), and the authors are free to give the text the structure that best suits their purposes. The articles should contain an unstructured abstract of maximum 250 words, can include all the figures and tables that the authors deem necessary, and have a maximum 100 references. We recommend following the PRISMA recommendations for this type of studies.
Letters to the Editor. This type of article is dedicated to the publication of original data that can be reported and discussed in no more than 1,500 text words (excluding tables, figure legends and references). Letters have no abstract, no headings, a maximum of three tables and/or figures, and no more than 15 references. Letter should start with a paragraph summarizing the rationale for the study and the major conclusions. When appropriate, the reporting recommendations detailed for Original articles should be followed. Letter can use Supplementary data for three additional figures and/or tables. The use of text in Supplementary data is not foreseen except for the legends of the figures and the titles of the tables (no Methods).
Case Reports & Case Series. Reports of special cases that contribute to a better understanding of hematological diseases or to patient care will be considered for publication. These reports need to be conclusive and must include pathogenetic insights in addition to the description of the clinical case(s). Only few Case Reports can be published and a strict selection is in place. Case Reports have no abstract, no headings, and a maximum of 1,500 words in the text (excluding tables, figure legends and references), a maximum of three tables and/or figures, and 15 references. Supplementary data can't be used.
Comments. This format is used to discuss a recently published article in Haematologica, or to discuss cutting edge ideas or developments in the broad field of hematology. Papers containing new data can not be published with this format. Comments have no abstract, a maximum of 1,000 words in the text and 10 essential references. Comments should not include figures or tables. Please start the comment with a paragraph summarizing the rationale for the comment, citing the article or articles that form the basis for the comment. No more than two authors are allowed.
We are very flexible on the format of the first submission and the rules described in the following sections do not necessarily all have to be respected .
At initial submission, only two PDF files will be requested:
One pdf file with the text, tables, and figures (please, make sure the file size is below 5 Mb)
One PDF file with all supplementary data
A revised manuscript must comply with all the editorial rules. The following files will be requested:
One word document with text and tables (indicate in color the changes that were made compared to the first submission)
One high quality file for each figure
One pdf file with all supplementary data
In case of changes in the authorship, please fill this form and submit it as supplemental file: Change of Authorship Form
Manuscript preparation
Manuscripts should be prepared according to the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations).
Manuscripts should be prepared using American English spelling. Scientific nomenclature should be used without Saxon Genitive (for example: use 'Hodgkin Lymphoma' and not 'Hodgkin's Lymphoma').
Abbreviations and acronyms should be used when a term that includes multiple words is used more than once in the Abstract and more than three times in the Main text. Abstract, Main Text and Figure legends should be considered as a separate entities and abbreviations must be explained in full text in all these items. Abbreviation and acronyms used in Tables must be explained in a note below the Table. Abbreviations should not be used in the title unless the abbreviation is better understood than the full designation, such as for DNA, which is more easily understood than Deoxyribonucleic acid. If this is the case, explain the abbreviation in the Abstract. Abreviations should not be written in the plural form.
Units and measurements. Use the SI system of units. Failure to use SI system in the figures requires that the authors redo them.
Drugs. Commercial names of drugs have to be avoided. Drugs should have be referred to under their generic names unless different proprietary versions are being discussed.
Genes and proteins. Use the official gene symbols when referring to genes, transcripts, proteins. (for example: Use ABL1, not ABL or c-ABL ; use MYC, not c-Myc). Use this database as a reference: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene. Human Genes' names have to be indicated in italic and capital, Human Proteins' names only in capital letter. Mouse and Rat Genes' names have to be indicated in italic, with only the first letter in capital and the remaining letters in lowercase (Shh). Mouse and Rat Proteins' names have to be indicated only in capital letter (SHH). Zebrafish and Frog (xenopus sp.) Genes' names have to be indicated in italic and all in lowercase (shh). Zebrafish and Frog (xenopus sp.) Proteins' names must have the first letter in capital and the remaining letters in lowercase.
Protection of human individuals in research. When reporting studies (prospective or retrospective) involving people, medical records, and human tissues, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Authors should also declare that any research involving people, medical records, and human tissues was approved by the relevant institutional review boards or ethics committees and that all human participants gave written informed consent (Haematologica reserves the right to ask the authors or the institution they indicated for a copy of the document). Patients have a right to privacy that should not be violated. Identifying information, including names, initials, or hospital numbers, should not be published. Photographs and any data that can lead to patient identification can be published only if this is essential for scientific purposes and the subject has signed a specific written informed consent.
Protection of animals in research. When performing experiments on animals or animal tissues, authors should seek approval by an institutional ethics committee and should strictly follow the institutional and national guide for the care and use of laboratory animals. We can only consider manuscripts reporting on studies on animals or animal tissues if ethical committee approval of the study can be documented.
Clinical trials. We request, as a condition for publication, the registration of all clinical trials in a public trials registry. The ICMJE provides specific guidelines on this topic. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. Haematologica does not advocate one particular registry, but follows the ICMJE recommendations. Because it is critical that trial registries are independent of for-profit interests, the ICMJE policy requires registration in a WHO primary registry rather than solely in an associate registry, since for-profit entities manage some associate registries.